MCID: HPT007
MIFTS: 52

Hepatitis E

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis E

MalaCards integrated aliases for Hepatitis E:

Name: Hepatitis E 12 74 52 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4411
MeSH 43 D016751
UMLS 71 C0085293

Summaries for Hepatitis E

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis E virus, which is transmitted by ingestion of contaminated food. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom dark urine, has symptom joint pain, and has symptom jaundice.

MalaCards based summary : Hepatitis E is related to acute liver failure and hepatic coma, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis E is AMBP (Alpha-1-Microglobulin/Bikunin Precursor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Measles. The drugs Ribavirin and Interferon-alpha have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : 74 Hepatitis E is inflammation of the liver caused by infection with the hepatitis E virus (HEV). Hepatitis... more...

Related Diseases for Hepatitis E

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis E via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 509)
# Related Disease Score Top Affiliating Genes
1 acute liver failure 31.5 GPT F2 ALB
2 hepatic coma 31.0 GPT F2 ALB
3 guillain-barre syndrome 30.8 TNF CD40LG ALB
4 hepatic encephalopathy 30.6 TNF GPT F2 ALB
5 non-a-e hepatitis 30.5 F2 ALB
6 acute kidney failure 30.5 GPT F2 ALB
7 hepatitis c virus 30.4 IFNG GRB2 GPT DDX58
8 cholecystitis 30.3 GPT F2 ALB
9 hepatitis 30.3 TNF IFNG GRB2 GPT GGT1 F2
10 hepatitis d 30.3 GPT F2 CD40LG
11 hepatorenal syndrome 30.2 GPT F2 ALB
12 cryoglobulinemia 30.2 TNF IFNG GPT CD40LG
13 liver cirrhosis 30.2 MIR122 GPT GGT1 F2 ALB
14 cholestasis 30.2 GPT GGT1 F2 ALB
15 polyradiculoneuropathy 30.1 IFNG CD40LG ALB
16 meningoencephalitis 30.1 TNF CD40LG ALB
17 hepatitis a 30.0 TNF TLR3 IFNG GPT GGT1 F2
18 encephalitis 30.0 TNF TLR3 DDX58 CD40LG
19 liver disease 29.9 TNF MIR122 GPT GGT1 F2 ALB
20 infantile liver failure syndrome 1 29.9 GPT F2 ALB
21 immune deficiency disease 29.9 TSG101 TNF IFNG GPT CD40LG
22 non-alcoholic steatohepatitis 29.9 TNF GPT GGT1
23 peritonitis 29.8 TNF IFNG F2 ALB
24 purpura 29.8 TNF F2 CD40LG
25 syphilis 29.8 GPT CD40LG ALB
26 disseminated intravascular coagulation 29.8 TNF GPT F2
27 hemophagocytic lymphohistiocytosis 29.8 TNF IFNG GPT
28 drug-induced hepatitis 29.8 TNF GPT ALB
29 leptospirosis 29.8 TNF IFNG F2 CD40LG
30 crimean-congo hemorrhagic fever 29.7 TNF GPT DDX58
31 viral encephalitis 29.7 TNF TLR3 CD40LG
32 glomerular disease 29.7 AMBP ALB
33 plague 29.6 TNF DDX58 ALB
34 poliomyelitis 29.6 TNF IFNG CD40LG
35 eclampsia 29.6 TNF F2 ALB
36 newcastle disease 29.6 TNF TLR3 DDX58
37 dengue disease 29.6 TNF GPT CD40LG ALB
38 pneumocystosis 29.6 TNF CD40LG ALB
39 amebiasis 29.6 TNF CD40LG ALB
40 dysentery 29.5 TNF CD40LG ALB
41 myocarditis 29.5 TNF TLR3 IFNG CD40LG ALB
42 toxic shock syndrome 29.5 TNF IFNG CD40LG
43 meningitis 29.5 TNF IFNG CD40LG ALB
44 brucellosis 29.5 TNF IFNG CD40LG
45 peripheral nervous system disease 29.5 TNF IFNG GPT CD40LG ALB
46 acute cholangitis 29.5 GPT GGT1 F2 ALB
47 acalculous cholecystitis 29.5 GPT F2 CD40LG ALB
48 exanthem 29.4 TNF GPT F2 CD40LG ALB
49 pericardial effusion 29.4 GPT F2 CD40LG ALB
50 tick-borne encephalitis 29.4 TLR3 GPT DDX58 ALB

Graphical network of the top 20 diseases related to Hepatitis E:



Diseases related to Hepatitis E

Symptoms & Phenotypes for Hepatitis E

Symptoms:

12
  • vomiting
  • fatigue
  • fever
  • abdominal pain
  • jaundice
  • nausea
  • dark urine
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

MGI Mouse Phenotypes related to Hepatitis E:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 ALB ASGR1 CD40LG DDX58 F2 FYN
2 endocrine/exocrine gland MP:0005379 10.17 ALB AMBP ASZ1 CD40LG FYN GGT1
3 hematopoietic system MP:0005397 10.14 ASGR1 CD40LG DDX58 F2 FYN GGT1
4 immune system MP:0005387 10.13 ALB ASGR1 CD40LG DDX58 F2 FYN
5 mortality/aging MP:0010768 10.07 ALB ASGR1 CD40LG DDX58 F2 FYN
6 neoplasm MP:0002006 9.7 ALB DDX58 GRB2 IFNG TLR3 TNF
7 renal/urinary system MP:0005367 9.56 ALB CD40LG FYN GGT1 GRB2 HPX
8 reproductive system MP:0005389 9.32 AMBP ASZ1 CD40LG F2 FYN GGT1

Drugs & Therapeutics for Hepatitis E

Drugs for Hepatitis E (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4 36791-04-5 37542
2 Interferon-alpha Phase 4
3 interferons Phase 4
4 Antiviral Agents Phase 4
5 Anti-Infective Agents Phase 4
6 Antimetabolites Phase 4
7
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
8
Aluminum sulfate Approved Phase 3 10043-01-3
9
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
10
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
11
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
12
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 70-16-6, 59-43-8 1130
13
Niacin Approved, Investigational, Nutraceutical Phase 2, Phase 3 59-67-6 938
14
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2, Phase 3 83-88-5 493570
15 Sunflower Phase 3
16 Vitamins Phase 2, Phase 3
17 Vitamin B Complex Phase 2, Phase 3
18 Vitamin B3 Phase 2, Phase 3
19 Vitamin B9 Phase 2, Phase 3
20 Antioxidants Phase 2, Phase 3
21 Vitamin B2 Phase 2, Phase 3
22 silymarin Phase 2, Phase 3
23 Protective Agents Phase 2, Phase 3
24 Folate Phase 2, Phase 3
25 Thiamin Phase 2, Phase 3
26 Nicotinic Acids Phase 2, Phase 3
27
Sofosbuvir Approved Phase 2 1190307-88-0 45375808
28
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
29
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
30
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
31 Dexelvucitabine Investigational Phase 2 134379-77-4
32
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
33 Anti-Retroviral Agents Phase 2
34 Reverse Transcriptase Inhibitors Phase 2
35 Anti-HIV Agents Phase 2
36 Pharmaceutical Solutions Phase 1
37
Permethrin Approved, Investigational 52645-53-1 40326
38
Resveratrol Approved, Experimental, Investigational 501-36-0 445154
39 Immunoglobulins
40 Antibodies
41 Anti-Inflammatory Agents
42 Platelet Aggregation Inhibitors
43 Anti-Inflammatory Agents, Non-Steroidal
44 Analgesics, Non-Narcotic
45 Antirheumatic Agents
46 Analgesics
47 Liver Extracts
48 Hematinics

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine(Hecolin®) in Seniors Aged Over 65 Years Completed NCT02189603 Phase 4
2 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years Completed NCT02417597 Phase 4
3 A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years) Completed NCT03168412 Phase 4
4 Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine Completed NCT02584543 Phase 4
5 An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over) Completed NCT02964910 Phase 4
6 A Study of Peg-interferon Treatment for Nucleos(t)Ide Analogues Suppressed Chronic Hepatitis B Patients With Low Level Hepatitis Surface Antigen Recruiting NCT04035837 Phase 4 pegylated interferon-alfa
7 An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
8 Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms Terminated NCT02558114 Phase 4 Ribavirin
9 An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency Withdrawn NCT03365921 Phase 4
10 A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine Unknown status NCT01014845 Phase 3
11 Field Trial of Maternal Influenza Immunization in Asia Unknown status NCT01034254 Phase 3
12 Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections Recruiting NCT03737669 Phase 3
13 A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women Active, not recruiting NCT01735006 Phase 3
14 A Multicentre, Double-blind, Randomized, Placebo-controlled, Phase II/III Study to Evaluate the Safety and Efficacy of 280 mg and 420 mg Silymarin TID (Legalon® Capsules) Administered for Four Weeks in Subjects With Acute Viral Hepatitis With a Four Week Follow-up Period Terminated NCT00755950 Phase 2, Phase 3
15 A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus Unknown status NCT01698723 Phase 2 Ribavirin;Placebo
16 HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Completed NCT03282474 Phase 2 Sofosbuvir
17 A Phase II, Prospective, Randomized, Double-blind, Placebo Controlled, Field Efficacy Trial of a Candidate Hepatitis E Vaccine in Nepal. Completed NCT00287469 Phase 2
18 A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults Completed NCT00034359 Phase 2 ACH-126, 443 (beta-L-Fd4C);Lamivudine;Placebo
19 Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive Completed NCT01204762 Phase 2 pegIFN;pegIFNα-2a;PegIFN lambda;Entecavir
20 A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years Active, not recruiting NCT02710851 Phase 2
21 A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus Active, not recruiting NCT02751996 Phase 2 SB 9200;Placebo;Tenofovir
22 A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China Completed NCT02603055 Phase 1
23 A Phase 1, Double-Blinded, Placebo Controlled, Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of HEV-239 (Hecolin(R)) in a Healthy US Adult Population Recruiting NCT03827395 Phase 1
24 Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study Unknown status NCT02809885
25 Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients Unknown status NCT02645955
26 The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study Unknown status NCT02419625
27 Natural Course of Acute Icteric Viral Hepatitis in Type II Diabetes Mellitus Patients and Non-Diabetic Patients:A Pilot Cohort Study Unknown status NCT00689546
28 Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille. Unknown status NCT02819128
29 A Prospective Multicenter Study of Acute on Chronic Liver Failure in China Unknown status NCT02457637
30 Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study Completed NCT02847507
31 Hepatitis E in the Organ Transplant Population Completed NCT02190253
32 Host Responses in Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection Completed NCT01090232
33 Role of Cytokines in Hepatitis E Virus Infection During Pregnancy Completed NCT01062321
34 A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors Completed NCT01858519
35 The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial. Completed NCT03546530 Interferon;Interferon+resveratrol
36 The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial Completed NCT03509688 entecavir+resveratrol;Entecavir;entecavir+thymosin α1
37 Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms. Recruiting NCT03524014
38 Observational Study on Seroprevalence of Hepatitis E Infection in Healthy Blood Donors in the Canton Ticino Recruiting NCT03601221
39 A Prospective Multi-center Validating Cohort for ACLF Diagnosis and Prognosis From Ch-CANONIC Study Active, not recruiting NCT03641872
40 Hepatitis E Virus Infection Among Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver Not yet recruiting NCT03488589

Search NIH Clinical Center for Hepatitis E

Cochrane evidence based reviews: hepatitis e

Genetic Tests for Hepatitis E

Anatomical Context for Hepatitis E

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis E:

19
Liver

MalaCards organs/tissues related to Hepatitis E:

40
Liver, Kidney, Testes, T Cells, Thyroid, Brain, Heart

Publications for Hepatitis E

Articles related to Hepatitis E:

(show top 50) (show all 4983)
# Title Authors PMID Year
1
Value of hepatitis E virus detection by cell culture compared with nested PCR and serological studies by IgM and IgG. 54 61
19374667 2009
2
A novel mycovirus that is related to the human pathogen hepatitis E virus and rubi-like viruses. 54 61
19073734 2009
3
Double-antigen enzyme-linked immunosorbent assay for detection of hepatitis E virus-specific antibodies in human or swine sera. 54 61
18495846 2008
4
Hepatitis E virus coinfection with hepatotropic viruses in Egyptian children. 54 61
18629421 2008
5
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. 54 61
16447107 2006
6
The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor. 54 61
16140784 2005
7
Prevalence of hepatitis E virus in Egyptian children presented with minor hepatic disorders. 54 61
17977212 2005
8
Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. 54 61
15634950 2005
9
Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus. 54 61
15221899 2004
10
The ORF3 protein of hepatitis E virus interacts with liver-specific alpha1-microglobulin and its precursor alpha1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. 54 61
15037615 2004
11
Molecular and serological characterization of sporadic acute hepatitis E in a Japanese patient infected with a genotype III hepatitis E virus in 1993. 54 61
12560575 2003
12
Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. 54 61
12204962 2002
13
Sero-epidemiology of hepatitis E virus (HEV) in urban and rural children of North India. 54 61
11359972 2001
14
Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic. 54 61
11060044 2000
15
[Dynamics of anti-HEV ORF2, ORF3, IgM and IgG in serial sera of patients with hepatitis E and their clinical significance]. 54 61
10923456 1998
16
Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. 54 61
9658374 1998
17
[Diagnosis of hepatitis E virus infection in sporadic acute hepatitis]. 54 61
15619831 1997
18
Acute sporadic hepatitis E virus infection in southern China. 54 61
8550986 1995
19
Changes of pre-S1 and pre-S2 antigens in sera of patients with hepatitis B virus infection. 54 61
2170220 1990
20
Seroprevalence of AIH-related autoantibodies in patients with acute hepatitis E viral infection: a prospective case-control study in China. 61
32037983 2020
21
Seroprevalence of hepatitis E virus among different age groups in Tehran, Iran. 61
31993207 2020
22
Multivesicular body sorting and the exosomal pathway are required for the release of rat hepatitis E virus from infected cells. 61
31962066 2020
23
Metagenomic analysis of viruses, bacteria and protozoa in irrigation water. 61
31978735 2020
24
Spontaneous Flares of Chronic Hepatitis B Virus in Hepatitis Be Antigen Negative Carriers Who Subsequently Clear Hepatitis B Surface Antigen. 61
32034604 2020
25
Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia. 61
31894559 2020
26
Chronic hepatitis E in absence of severe immune deficiency. 61
31327621 2020
27
Prevalence of hepatitis E viraemia among blood donors: a systematic review. 61
32030767 2020
28
Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. 61
31756566 2020
29
Detection of hepatitis E virus RNA in rats caught in pig farms from Northern Italy. 61
31592576 2020
30
Does HEV-3 subtype play a role in the severity of acute hepatitis E? 61
31837187 2020
31
Evaluation of a molecular method for hepatitis E virus (HEV) detection in pancreatin of porcine origin. 61
31770544 2020
32
Exposure to hepatitis E virus in hemodialysis patients from west-central Poland. 61
32017168 2020
33
A Systematic Review of the Extra-Hepatic Manifestations of Hepatitis E Virus Infection. 61
32033102 2020
34
Hepatitis E Virus in Pigs from Slaughterhouses, United States, 2017-2019. 61
31961315 2020
35
Comparative evaluation of two immunoassays for serological diagnosis of hepatitis E. 61
31579928 2020
36
A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan. 61
31205267 2020
37
Serological Survey on Bacterial and Viral Pathogens in Wild Boars Hunted in Tuscany. 61
32034585 2020
38
Comparative genomics of hepatitis A virus, hepatitis C virus, and hepatitis E virus provides insights into the evolutionary history of Hepatovirus species. 61
31742930 2020
39
Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation. 61
31963175 2020
40
Hepatitis E virus finds its path through the gut. 61
31915238 2020
41
Hepatitis E virus infection in Hong Kong blood donors. 61
31709559 2020
42
The U-Rich Untranslated Region of the Hepatitis E Virus Induces Differential Type I and Type III Interferon Responses in a Host Cell-Dependent Manner. 61
31937650 2020
43
HEV study protocol : design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. 61
31959609 2020
44
Four-year long (2014-2017) clinical and laboratory surveillance of hepatitis E virus infections using combined antibody, molecular, antigen and avidity detection methods: Increasing incidence and chronic HEV case in Hungary. 61
32007844 2020
45
Robust hepatitis E virus infection and transcriptional response in human hepatocytes. 61
31896581 2020
46
Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature. 61
31828968 2020
47
Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 61
30072282 2020
48
Hepatitis E genotype 1 outbreak in Jharkhand, India: A descriptive analysis. 61
31957617 2020
49
Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. 61
31991629 2020
50
The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy. 61
31902599 2020

Variations for Hepatitis E

Expression for Hepatitis E

Search GEO for disease gene expression data for Hepatitis E.

Pathways for Hepatitis E

Pathways related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 TNF ISG15 IFNG GRB2 FYN DDX58
2
Show member pathways
12.63 TNF TLR3 ISG15 IFNG DDX58
3
Show member pathways
12.54 TNF TLR3 ISG15 IFNG DDX58
4
Show member pathways
12.39 TNF IFNG GRB2 FYN CD40LG
5
Show member pathways
12.26 TNF IFNG GRB2 FYN CD40LG
6
Show member pathways
12.19 TNF IFNG GRB2 FYN F2
7
Show member pathways
12.13 TNF TLR3 IFNG GRB2
8 12.07 TNF TLR3 IFNG DDX58 CD40LG
9 11.89 TNF TLR3 IFNG GRB2
10
Show member pathways
11.55 TNF IFNG CD40LG
11
Show member pathways
11.43 TNF IFNG CD40LG
12 11.36 TNF IFNG GRB2 FYN
13
Show member pathways
11.35 TNF IFNG GGT1 F2 ALB
14 11.28 TNF IFNG CD40LG

GO Terms for Hepatitis E

Cellular components related to Hepatitis E according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 TNF ISG15 IFNG HPX F2 CD40LG
2 extracellular exosome GO:0070062 9.81 TSG101 MIR122 HPX GRB2 GPT GGT1
3 extracellular space GO:0005615 9.36 TNF TLR3 MIR122 IFNG HPX GPT
4 blood microparticle GO:0072562 9.26 HPX F2 AMBP ALB

Biological processes related to Hepatitis E according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.89 TLR3 ISG15 IFNG DDX58
2 leukocyte migration GO:0050900 9.88 TNF GRB2 FYN F2
3 receptor-mediated endocytosis GO:0006898 9.84 HPX ASGR1 AMBP ALB
4 positive regulation of interleukin-6 production GO:0032755 9.75 TNF TLR3 DDX58
5 response to virus GO:0009615 9.73 TNF TLR3 IFNG DDX58
6 T cell costimulation GO:0031295 9.72 GRB2 FYN CD40LG
7 extrinsic apoptotic signaling pathway GO:0097191 9.67 TNF TLR3 IFNG
8 microglial cell activation GO:0001774 9.63 TNF TLR3 IFNG
9 negative regulation of amyloid-beta clearance GO:1900222 9.6 TNF IFNG
10 positive regulation of interleukin-8 production GO:0032757 9.58 TNF TLR3 DDX58
11 necroptotic signaling pathway GO:0097527 9.57 TNF TLR3
12 detection of virus GO:0009597 9.56 TLR3 DDX58
13 positive regulation of interleukin-12 production GO:0032735 9.54 TLR3 IFNG CD40LG
14 regulation of immunoglobulin secretion GO:0051023 9.52 TNF CD40LG
15 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.51 TNF HPX
16 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IFNG
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 TNF IFNG HPX FYN
18 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 TNF IFNG
19 positive regulation of nitrogen compound metabolic process GO:0051173 9.26 TNF IFNG
20 viral process GO:0016032 9.23 TSG101 ISG15 HPX GRB2 FYN DDX58
21 positive regulation of chemokine biosynthetic process GO:0045080 9.13 TNF TLR3 IFNG

Sources for Hepatitis E

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....